New drug JUV-161 takes first step in human safety trial
NCT ID NCT06918925
First seen Jan 30, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This early-stage study tests JUV-161 for the first time in people. It aims to check safety and how the drug moves through the body in 72 healthy adults aged 18 to 60. Results will help plan future studies in patients with muscle diseases like myotonic dystrophy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.